NEW YORK ( TheStreet) - Last week I wrote, Hotels, Booze and Drugs Headline This Week's Earnings and this morning I provide a scorecard for the five companies that reported results.The two companies that represented drugs and booze were the performance winners, while the company that provides construction materials was the biggest loser. We enter the week with 77% of all stocks overvalued with 40.8% overvalued by 20% or more. Fifteen of 16 sectors are overvalued, 13 by double-digit percentages and with seven overvalued by more than 20%. Here's Today's Earnings Scorecard: Monsanto ( MON) ($105.63) missed EPS estimates by four cents losing 47 cents a share premarket on Oct. 2. The stock slipped to $101.78 into Oct. 2 holding the 200-day simple moving average at $101.94. Monsanto still has a sell rating with a monthly pivot at $102.38 and weekly risky level at $107.33. Monsanto stock rebounded from its 200-day SMA on the pending acquisition of the Climate Corp., a software company that analyzes agriculture data. Customized data mining of farming data will be combined with Monsanto's R&D efforts to help farmers increase output while reducing the resources necessary to so. PAYX) ($39.55) beat EPS estimates by a penny earning 44 cents a share in afterhours trading on Sept. 30. The stock moved sideways to down to a low for the week at $39.35 on Oct. 4, below the 50-day SMA at $39.86. Paychex maintains a hold rating with a weekly value level at $38.99 and monthly risky level at $42.40. The payroll processing firm made some comments on the impact on the partial shutdown of the U.S. government including their estimation that 1 million U.S. federal workers could be furloughed. In addition they said that small businesses and individuals planning international travel would not be able to obtain a passport or visas. STZ) ($61.97) beat EPS estimates by 7 cents earning 96 cents a share before the open on Oct. 3. The stock opened higher and set a new multi-year high at $62.15 on Oct. 4 testing my September monthly risky level at $62.23. Constellation Brands maintains a hold rating with weekly and quarterly value levels at $60.98 and $60.58 and a new monthly risky level at $71.53.